David A. Siegel Solid Biosciences Inc. Call Options Transaction History

Two Sigma Advisers, LP

  • $41.3 Billion
  • Q3 2024

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

Others Institutions Holding SLDB

# of Institutions
2
Shares Held
97
Call Options Held
0
Put Options Held
0
View Full List

About Solid Biosciences Inc.

SLDB Quotes by TradingView
  • Ticker SLDB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 7,533,080
  • Market Cap $30.4M
  • Description
  • Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...
More about SLDB
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email